STOCK TITAN
  1. Home
  2. News
  3. IINN

Inspira Technologies Oxy Bhn Ltd - IINN STOCK NEWS

Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.

Inspira Technologies Oxy BHN Ltd (IINN) delivers innovative respiratory care solutions through its non-invasive INSPIRA ART system and HYLA blood monitoring technology. This page provides investors and healthcare professionals with essential updates on regulatory milestones, product developments, and clinical partnerships shaping the future of critical care.

Access real-time information on FDA clearances, technology evaluations, and strategic collaborations. Our curated news ensures you stay informed about advancements in extracorporeal oxygenation and AI-driven blood analytics without speculative commentary.

Discover updates across key categories including regulatory submissions, clinical trial results, product launches, and global distribution agreements. All content is verified for accuracy and relevance to support informed decision-making.

Bookmark this page for streamlined access to Inspira Technologies' progress in redefining respiratory support systems. Check back regularly for authoritative reporting on innovations addressing acute respiratory failure and ICU resource challenges.

News

Inspira™ Announces Plans to Report the Primary Results for a Core Blood Oxygenation Technology Within Days

Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. announces a major milestone in core blood oxygenation technology with INSPIRA ART (Gen 2), aiming to revolutionize the medical device market. Anticipated FDA clearance for INSPIRA ART100 (Gen 1) in 2024 to address a $1.16 billion market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
conferences
-
News

Inspira™ To Host Conference Call to Discuss Investor Presentation and Announce Next Major Milestone

Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) announces an Investor Presentation to reveal a major milestone regarding their breakthrough Augmented Respiration Technology. The technology aims to rebalance patient oxygen levels without invasive ventilation systems. The Company President, Mr. Joe Hayon, will present the details on March 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.42%
Tags
conferences
-
News

Inspira™ Announces Breakthrough Update: Nears First FDA 510(k) Approval, 3 U.S. Patents Approved, $546 million in Summary Distribution Agreements

Rhea-AI Summary
Inspira Technologies progresses towards FDA 510(k) clearance for INSPIRA ART100 device, plans additional submissions for HYLA blood sensor and INSPIRA ART disposables. Company revolutionizing mechanical ventilator market with proprietary technologies. Signed $546 million in distribution agreements. President emphasizes the importance of HYLA blood sensor in delivering oxygen. Breakthrough patents approved by USPTO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.42%
Tags
none
News

Inspira™ introduces high-end platform for bio-mimicking blood parameters for development and testing of core technologies

Rhea-AI Summary
Inspira Technologies unveils breakthrough blood simulation capability to advance medical technologies. The platform aims to reduce time and costs, accelerate development, and improve validation processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
none
-
News

Inspira™ Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System

Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. receives U.S. Patent approval for orbiting blood oxygenation delivery system, a core technology of the INSPIRA ART500 device. The system is designed to revolutionize medical oxygenation by eliminating damage caused by fiber membranes. CEO Dagi Ben-Noon hails it as a monumental advancement in blood oxygenation technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.42%
Tags
none
-
News

Inspira™ Technologies Collaborates with a Leading Israeli Medical Center for Clinical Evaluation of INSPIRA™ ART Device

Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) has announced a non-binding Letter of Intent (LOI) with Shamir Medical Center to assess the integration and performance of the INSPIRA™ ART100 device within the hospital's clinical environment. The LOI solidifies the mutual commitment of both parties to evaluate the device's fit, efficiency, and overall impact on healthcare delivery. The collaboration aims to enhance life-support care and establish a pathway for adoption in local and international markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
none
News

Inspira™ Technologies Signs Strategic Agreement to Enter Gulf States with Glo-Med for Deployment of 531 INSPIRA™ ART Devices

Rhea-AI Summary
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) has announced a summary distribution agreement with Glo-Med Networks, Inc. to potentially provide $32.6 million over a 5-year period. The agreement designates Glo-Med as the exclusive distributor in Saudi Arabia, United Arab Emirates, and Bahrain for the INSPIRA™ ART devices. The agreement is subject to regulatory approvals and is seen as a significant step for both companies in broadening their range of innovative products in the healthcare market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.87%
Tags
none
-
News

Inspira™ Announces Plans to Launch and Target Single-Use Disposable Blood Oxygenation Kit for a New Disposable Perfusion Market Opportunity

Rhea-AI Summary
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) announces the development of a single-use disposable blood oxygenation kit for its INSPIRA ART medical device series, targeting FDA authorization in 2025. The kit is designed to be compatible with various life support machines, potentially reducing hospital costs. CEO Dagi Ben-Noon anticipates revenue streams based on the disposable razorblade business model, along with the FDA clearance of the INSPIRA™ ART100 device in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.24%
Tags
none
-
News

Inspira™ Technologies Signs Letter of Intent with Northwestern Memorial Hospital in Chicago for Clinical Use of INSPIRA™ ART100 Device

Rhea-AI Summary
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) has signed a non-binding Letter of Intent with Northwestern Memorial Hospital, a top-ranked hospital in the United States, to explore collaboration for the evaluation of its INSPIRA ART100 device. The agreement is subject to FDA clearance and entering a definitive evaluation agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
none
News

Inspira™ Technologies Closes on $3.88 Million Registered Direct Offering

Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) has closed a registered direct offering of 3,031,250 ordinary shares at a purchase price of $1.28 per share, with aggregate gross proceeds of approximately $3.88 million. The company also issued warrants to purchase up to an aggregate of 3,031,250 ordinary shares at an exercise price of $1.28 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
offering
Stock IINN logo
Inspira Technologies Oxy Bhn Ltd

Nasdaq:IINN

IINN Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

IINN Stock Data

15.02M
24.59M
4.01%
4.55%
0.61%
Medical Devices
Healthcare
Link
Israel
Ra'anana